Helicobacter Pylori Infections Market Outlook 2034: Clinical Trials, Prevalence, Emerging Therapies, Regulatory Approvals, Market Statistics, Revenues, and Key Companies by DelveInsight

The Helicobacter Pylori Infections market is being actively shaped by leading pharmaceutical and biotech companies such as Servatus Biopharmaceuticals, Cinclus Pharma Holding AB, Crestone, EpiVax, Iguana Biotechnology, ImevaX GmbH, ImmunoBiology, Luoxin Pharmaceuticals, Nexbiome Therapeutics, Recce Pharmaceuticals, RedHill Biopharma Ltd, SCG Cell Therapy Pte Ltd, Shanghai High-Tech Bioengineering Co Ltd, Takeda Pharmaceutical, TenNor Therapeutics, Trio Medicines, Xiamen Encheng Pharmaceutical Co Ltd, among several others.

(Albany, USA) DelveInsight's latest report, "Helicobacter Pylori Infections Market Insights, Epidemiology, and Market Forecast-2034," offers a detailed evaluation of Helicobacter Pylori Infections. The study includes historical as well as projected epidemiology and analyzes the market dynamics across the United States, the five major European markets (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The comprehensive report highlights existing treatment practices, drugs currently under development, market share distribution of approved therapies, and the expected market size between 2020 and 2034 across seven major markets. It further reviews treatment algorithms, current medical practices, market drivers, challenges, and gaps in therapy, aiming to uncover the most promising opportunities and untapped potential within the Helicobacter Pylori Infections landscape.

Request a Free Sample Report @ Helicobacter Pylori Infections Market Forecast - https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Helicobacter Pylori Infections Market Report:
• DelveInsight projects that the market size for Helicobacter Pylori Infections will expand steadily, achieving a significant CAGR by 2034.
• Major industry players include Servatus Biopharmaceuticals, Cinclus Pharma Holding AB, Crestone, EpiVax, Iguana Biotechnology, ImevaX GmbH, ImmunoBiology, Luoxin Pharmaceuticals, Nexbiome Therapeutics, Recce Pharmaceuticals, RedHill Biopharma Ltd, SCG Cell Therapy Pte Ltd, Shanghai High-Tech Bioengineering Co Ltd, Takeda Pharmaceutical, TenNor Therapeutics, Trio Medicines, Xiamen Encheng Pharmaceutical Co Ltd, and more.
• Several late-stage and emerging therapies anticipated to launch include Rifasutenizole (TNP-2198), SVT1C4610, Vonoprazan, SQ 109, Tegoprazan, IMX 101, CRS3123, among others.
• March 2025: TenNor Therapeutics Inc. reported positive results from a Phase III trial assessing Rifasutenizol (TNP-2198) in combination with Rabeprazole and Amoxicillin for first-line treatment of H. pylori infection.
• February 2025: TenNor released findings from a Phase I, placebo-controlled study evaluating the pharmacokinetics and preliminary efficacy of multiple doses of TNP-2092 in healthy participants with Helicobacter Pylori infection.
• December 2024: Daewoong Pharmaceutical Co. LTD disclosed results from a multicenter Phase III trial of its DWP14012-based triple therapy regimen, confirming strong efficacy in H. pylori eradication.
• November 2024: TenNor Therapeutics announced that Rifasutenizol exceeded expectations in a pivotal Phase III study, achieving over 90% eradication and surpassing the standard bismuth-containing quadruple therapy (BQT).
• March 2024: A study in Yemen demonstrated that stool antigen tests (SAT) combined with H. pylori IgG antibody assays were highly accurate in distinguishing acute from chronic infections among patients.
• September 2022: The US FDA granted linaprazan glurate Qualified Infectious Disease Product (QIDP) designation for H. pylori infection treatment.
• In China, a Phase III clinical program is exploring population-wide screening and eradication strategies to reduce gastric cancer incidence, supported by FDA IND clearance and QIDP status.
• In 2022, the US FDA approved Phathom Pharmaceuticals' VOQUEZNA therapy packs-available in both triple and dual therapy formats-combining vonoprazan with antibiotics for effective treatment.

Helicobacter Pylori Infections Overview
Helicobacter pylori (H. pylori) is a widespread bacterial pathogen infecting the gastric lining and linked to multiple gastrointestinal conditions. Roughly two-thirds of the global population carry this bacterium, primarily transmitted via contaminated food, water, or direct contact with infected bodily fluids. While often asymptomatic, the infection may result in gastritis, peptic ulcers, or, in severe cases, gastric carcinoma. Clinical symptoms range from abdominal discomfort, nausea, and bloating to appetite loss. Diagnostic tools include breath tests, stool assays, serological tests, and endoscopic procedures. Treatment typically involves a combination of antibiotics and acid-suppressive therapy, and early intervention is crucial to preventing serious complications.

Know the projected market share of Helicobacter Pylori Infections in 7MM by 2034 @ - https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Helicobacter Pylori Infections Market Outlook
In 2022, the H. pylori infection market across the 7MM was valued at USD 2.67 billion, led by the US (USD 1.06B), EU4+UK (USD 1.03B), and Japan (USD 579M). Growth is expected through 2034, driven by rising awareness and new therapies.

Approved therapies include TALICIA (RedHill Biopharma), a rifabutin-based regimen, and VOQUEZNA (Phathom Pharmaceuticals), a P-CAB combination launched in the US in 2023. Additional marketed options include OMECLAMOX-Pak, PYLERA, and several Japan-specific regimens. The pipeline is limited, though rifasutenizole (TNP-2198) from TenNor Therapeutics is a notable late-stage candidate.

Helicobacter Pylori Infections Epidemiology
In 2022, the 7MM reported around 321.2 million diagnosed cases of Helicobacter pylori infection. The US contributed about 37% (118.6 million cases), the EU4 and UK combined represented 43% (138.4 million cases), and Japan accounted for the remaining 20%. Within Europe, France recorded the highest prevalence (23%), followed by Germany and Italy, while the UK had the lowest. In the US, the infection showed a male predominance (52% males vs. 48% females). Cases across regions are projected to rise throughout 2020-2034 due to growing disease awareness and improved diagnosis.

📌 Download report to learn how diagnostics will expand the diagnosed prevalence pool for H. pylori infections @ Helicobacter Pylori Infections Prevalence - https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Helicobacter Pylori Infections Pipeline Development and Drug Uptake Analysis
Rifasutenizole (TNP-2198) - TenNor Therapeutics
Rifasutenizole (TNP-2198) is a multitargeting conjugate with strong bactericidal activity against drug-resistant H. pylori strains and a low risk of resistance. Backed by China's National Major New Drug Innovation grant, it has received IND approval and QIDP designation from the US FDA. To date, five clinical trials have been completed in China, and a Phase III trial is ongoing in both China and the US, evaluating a simplified, safe eradication regimen that aligns with urea breath test (UBT) screening. The therapy also shows potential for large-scale prevention of gastric cancer in high-risk regions. Additionally, TNP-2198 is in Phase II trials for Clostridioides difficile infection and bacterial vaginosis.

Drug Class Insights for H. pylori
Proton Pump Inhibitors (PPIs) such as omeprazole, lansoprazole, pantoprazole, rabeprazole, and esomeprazole are first-line agents. They lower stomach acid, making the environment less favorable for H. pylori.

Combination therapy with PPIs and antibiotics is the standard of care. Common antibiotics include clarithromycin, amoxicillin, metronidazole, rifabutin, and tetracycline, each targeting the bacteria differently to prevent resistance.

Antibacterial mechanisms: clarithromycin (inhibits protein synthesis), amoxicillin (disrupts cell wall), metronidazole (damages DNA), tetracycline (blocks protein synthesis).

Antisecretory role: PPIs suppress gastric acid, improving antibiotic efficacy and aiding ulcer/gastritis healing.

Marketed Therapies
TALICIA (RHB-105) by RedHill Biopharma: a fixed-dose triple therapy (omeprazole + amoxicillin + rifabutin) for adult H. pylori infection, designed to reduce resistance and improve eradication rates.

TAKECAB (vonoprazan/TAK-438) by Takeda: a potassium-competitive acid blocker (P-CAB) offering stronger and longer-lasting acid suppression compared to traditional PPIs, making it a potent option for acid-related conditions including H. pylori infection.

Find out which top 3 therapies are expected to dominate market share by 2034 @ https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Helicobacter Pylori Infections Therapeutics Assessment
A number of pharmaceutical and biotech leaders-including Servatus Biopharmaceuticals, Cinclus Pharma Holding AB, Crestone, EpiVax, Iguana Biotechnology, ImevaX GmbH, ImmunoBiology, Luoxin Pharmaceuticals, Nexbiome Therapeutics, Recce Pharmaceuticals, RedHill Biopharma Ltd, SCG Cell Therapy Pte Ltd, Shanghai High-Tech Bioengineering Co Ltd, Takeda Pharmaceutical, TenNor Therapeutics, Trio Medicines, and Xiamen Encheng Pharmaceutical Co Ltd-are at the forefront of developing novel therapeutic approaches, which are expected to transform the H. pylori treatment landscape in the coming decade.

Discover how Rifasutenizole (TNP-2198) and SVT1C4610 are anticipated to influence the market CAGR @ Helicobacter Pylori Infections Therapeutics Market - https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Insights of the Report
• H. pylori patient population trends
• Market size projections and growth patterns
• Competitive landscape and cross-therapy analysis
• Market drivers and barriers
• Emerging opportunities
• New therapeutic approaches
• Pipeline evaluations
• Treatment practices and algorithms
• Impact of novel therapies on future market dynamics

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.